tradingkey.logo

Jade Biosciences Ord Shs

JBIO
15.470USD
+0.490+3.27%
交易中 美东报价延迟15分钟
504.74M总市值
亏损市盈率 TTM

Jade Biosciences Ord Shs

15.470
+0.490+3.27%

关于 公司

Jade Biosciences Ord Shs简介

公司代码- -
公司名称- -
上市日期- -
CEO- -
员工数量- -
证券类型- -
年结日- -
公司地址- -
城市- -
上市交易所- -
国家- -
邮编- -
电话- -
网址- -
公司代码- -
上市日期- -
CEO- -

Jade Biosciences Ord Shs公司高管

名称
名称/职务
职务
持股
持股变动
Dr. Benjamin T. Dake, Ph.D.
Dr. Benjamin T. Dake, Ph.D.
President, Chief Operating Officer, Secretary
President, Chief Operating Officer, Secretary
505.00
+9.31%
Mr. Habib Joseph Dable
Mr. Habib Joseph Dable
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Bradford D. (Brad) Dahms
Mr. Bradford D. (Brad) Dahms
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. Ralph Niven, Ph.D.
Dr. Ralph Niven, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Stephen K. Yu
Mr. Stephen K. Yu
Senior Vice President - Quality
Senior Vice President - Quality
--
--
Dr. Joshua Resnick, M.D.
Dr. Joshua Resnick, M.D.
Independent Director
Independent Director
--
--
Dr. Marinus Verwijs, Ph.D.
Dr. Marinus Verwijs, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
Dr. David S. Grayzel, M.D.
Dr. David S. Grayzel, M.D.
Independent Director
Independent Director
--
--
Ms. Allison Dorval, CPA
Ms. Allison Dorval, CPA
Independent Director
Independent Director
--
--
Mrs. Susan Fischer
Mrs. Susan Fischer
Executive Vice President - Development Operations
Executive Vice President - Development Operations
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Benjamin T. Dake, Ph.D.
Dr. Benjamin T. Dake, Ph.D.
President, Chief Operating Officer, Secretary
President, Chief Operating Officer, Secretary
505.00
+9.31%
Mr. Habib Joseph Dable
Mr. Habib Joseph Dable
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Bradford D. (Brad) Dahms
Mr. Bradford D. (Brad) Dahms
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. Ralph Niven, Ph.D.
Dr. Ralph Niven, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Stephen K. Yu
Mr. Stephen K. Yu
Senior Vice President - Quality
Senior Vice President - Quality
--
--
Dr. Joshua Resnick, M.D.
Dr. Joshua Resnick, M.D.
Independent Director
Independent Director
--
--

收入明细

由于公司未披露,未能获取相关数据
由于公司未披露,未能获取相关数据
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 12月10日 周三
更新时间: 12月10日 周三
持股股东
股东类型
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
10.41%
Fairmount Funds Management LLC
9.90%
VR Adviser, LLC
7.00%
RA Capital Management, LP
6.99%
Janus Henderson Investors
6.66%
其他
59.04%
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
10.41%
Fairmount Funds Management LLC
9.90%
VR Adviser, LLC
7.00%
RA Capital Management, LP
6.99%
Janus Henderson Investors
6.66%
其他
59.04%
股东类型
持股股东
占比
Hedge Fund
22.92%
Venture Capital
20.14%
Investment Advisor
19.66%
Investment Advisor/Hedge Fund
16.63%
Private Equity
4.23%
Individual Investor
0.95%
Research Firm
0.50%
Bank and Trust
0.08%
Pension Fund
0.02%
其他
14.86%

机构持股

更新时间: 12月9日 周二
更新时间: 12月9日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q4
215
38.72M
84.16%
+6.13M
2025Q3
219
31.65M
77.53%
-1.17M
2025Q2
222
32.33M
102.43%
+21.99M
2025Q1
207
926.72K
111.95%
-347.50K
2024Q4
207
879.69K
106.31%
-203.28K
2024Q3
202
808.07K
98.05%
-248.23K
2024Q2
199
794.81K
96.63%
-106.00K
2024Q1
171
831.84K
104.51%
-50.52K
2023Q4
165
824.02K
104.24%
-56.42K
2023Q3
162
814.98K
103.17%
-89.07K
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Fidelity Management & Research Company LLC
4.79M
10.41%
+53.40K
+1.13%
Sep 30, 2025
Fairmount Funds Management LLC
3.22M
9.87%
--
--
Sep 30, 2025
VR Adviser, LLC
3.22M
9.87%
--
--
Sep 30, 2025
RA Capital Management, LP
1.06M
3.26%
--
--
Sep 30, 2025
Deep Track Capital LP
2.28M
6.99%
-229.41K
-9.14%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
1.96M
4.26%
+401.34K
+25.73%
Sep 30, 2025
The Vanguard Group, Inc.
1.73M
3.75%
-80.84K
-4.47%
Sep 30, 2025
Versant Ventures
1.53M
3.32%
--
--
Sep 30, 2025
RTW Investments L.P.
1.45M
3.15%
--
--
Sep 30, 2025
查看更多

持股ETF

更新时间: 12月9日 周二
更新时间: 12月9日 周二
机构名称
占比
iShares Micro-Cap ETF
0.08%
iShares Russell 2000 Value ETF
0.03%
Global X Russell 2000 ETF
0.02%
Invesco Russell 2000 Dynamic Multifactor ETF
0.02%
ProShares Hedge Replication ETF
0.02%
ProShares UltraPro Russell2000
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0.01%
iShares Russell 3000 ETF
0%
iShares Russell 2000 Growth ETF
0%
查看更多
iShares Micro-Cap ETF
占比0.08%
iShares Russell 2000 Value ETF
占比0.03%
Global X Russell 2000 ETF
占比0.02%
Invesco Russell 2000 Dynamic Multifactor ETF
占比0.02%
ProShares Hedge Replication ETF
占比0.02%
ProShares UltraPro Russell2000
占比0.01%
Proshares Ultra Russell 2000
占比0.01%
iShares Russell 2000 ETF
占比0.01%
iShares Russell 3000 ETF
占比0%
iShares Russell 2000 Growth ETF
占比0%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
Apr 21, 2025
Merger
35→1
公告日期
类型
比率
Apr 21, 2025
Merger
35→1

常见问题

Jade Biosciences Ord Shs的前五大股东是谁?

Jade Biosciences Ord Shs 的前五大股东如下:
Fidelity Management & Research Company LLC持有股份:4.79M,占总股份比例:10.41%。
Fairmount Funds Management LLC持有股份:3.22M,占总股份比例:9.87%。
VR Adviser, LLC持有股份:3.22M,占总股份比例:9.87%。
RA Capital Management, LP持有股份:1.06M,占总股份比例:3.26%。
Deep Track Capital LP持有股份:2.28M,占总股份比例:6.99%。

Jade Biosciences Ord Shs的前三大股东类型是什么?

Jade Biosciences Ord Shs 的前三大股东类型分别是:
Fidelity Management & Research Company LLC
Fairmount Funds Management LLC
VR Adviser, LLC

有多少机构持有Jade Biosciences Ord Shs(JBIO)的股份?

截至2025Q4,共有215家机构持有Jade Biosciences Ord Shs的股份,合计持有的股份价值约为38.72M,占公司总股份的84.16%。与2025Q3相比,机构持股有所增加,增幅为6.63%。

哪个业务部门对Jade Biosciences Ord Shs的收入贡献最大?

在--,--业务部门对Jade Biosciences Ord Shs的收入贡献最大,创收--,占总收入的--%。
KeyAI